VMCO-1 is under clinical development by Nanoscope Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect VMCO-1’s likelihood of approval (LoA) and phase transition for Retinitis Pigmentosa (Retinitis) took place on 12 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their VMCO-1 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

VMCO-1 overview

VMCO-1 is under development for the treatment of juvenile macular degeneration (Stargardt Disease), dry age-related macular degeneration (geographic atrophy),  retinitis pigmentosa, usher syndrome and cone-rod dystrophy. It is administered by intravitreal route. The therapeutic candidate is a multi-characteristic broad-band light activatable white-opsin developed by MultiSite Gateway Technology. The technology uses a fusion Adeno-associated virus (AAV) vector with three plasmids encoding opsins with spectrally-separated activation peaks (ChR2 in blue, C1V1 in green and ReaChR in red).

Nanoscope Therapeutics overview

Nanoscope Therapeutics., is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight. The company is headquartered in United States.

Quick View VMCO-1 LOA Data

Report Segments
  • Innovator
Drug Name
  • VMCO-1
Administration Pathway
  • Intravitreal
Therapeutic Areas
  • Genetic Disorders
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.